Arvinas Expands LRRK2 Research with Michael J. Fox Foundation Programs
Event summary
- Arvinas joined the LITE and PPMI programs to advance ARV-102, a PROTAC targeting LRRK2 for Parkinson’s disease and PSP.
- ARV-102 is an orally bioavailable, brain-penetrant PROTAC designed to degrade LRRK2.
- Arvinas plans to initiate a Phase 1b and potentially a registrational Phase 2 clinical trial for ARV-102 in PSP patients in 2H 2026.
- The LITE program and PPMI aim to accelerate LRRK2-targeted therapies and gather robust open-access data for Parkinson’s research.
The big picture
Arvinas’ participation in the LITE and PPMI programs underscores the growing emphasis on collaborative, open-science initiatives in neurodegenerative disease research. The focus on LRRK2-targeted therapies aligns with broader industry trends toward precision medicine and biomarker-driven drug development. With ARV-102’s potential to address both Parkinson’s and PSP, Arvinas is positioning itself at the forefront of a critical therapeutic area.
What we're watching
- Clinical Development
- The pace at which ARV-102 advances through Phase 1b and Phase 2 trials will determine its potential as a Parkinson’s and PSP treatment.
- Collaborative Research
- How effectively Arvinas leverages the LITE and PPMI programs to deepen LRRK2 biology understanding and accelerate drug development.
- Market Differentiation
- Whether Arvinas’ targeted protein degradation approach can establish a competitive edge in the neurodegenerative disease space.
Related topics